Literature DB >> 24389035

Recent developments and current concepts in medulloblastoma.

N U Gerber1, M Mynarek2, K von Hoff3, C Friedrich4, A Resch5, S Rutkowski6.   

Abstract

Medulloblastoma is the most common malignant brain tumor of childhood. While prognosis has significantly improved in the last decades with multimodal therapy including surgery, radiotherapy, and chemotherapy, one third of patients still succumb to their disease. Further research is needed to find more efficient treatment strategies for prognostically unfavorable patient groups and to minimize long-term sequelae of tumor treatment. This review gives a summary of the current state of treatment concepts including an outlook on the near future. We describe recent advances in the understanding of molecular mechanisms, their potential impact on risk stratification in upcoming clinical trials, and perspectives for the clinical implementation of targeted therapies.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  (MeSH): Medulloblastoma; Brain neoplasms; Cancer; Child; Molecular targeted therapy; Therapy

Mesh:

Year:  2013        PMID: 24389035     DOI: 10.1016/j.ctrv.2013.11.010

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  34 in total

Review 1.  Therapeutic strategies to improve drug delivery across the blood-brain barrier.

Authors:  Tej D Azad; James Pan; Ian D Connolly; Austin Remington; Christy M Wilson; Gerald A Grant
Journal:  Neurosurg Focus       Date:  2015-03       Impact factor: 4.047

Review 2.  Subfrontal recurrence after cerebellar medulloblastoma resection without local relapse: case-based update.

Authors:  He Yue; Wang Ling; Ou Yibo; Wang Sheng; Tang Sicheng; Chen Jincao; Guo Dongsheng
Journal:  Childs Nerv Syst       Date:  2018-06-23       Impact factor: 1.475

Review 3.  Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities.

Authors:  John Glod; Gilbert J Rahme; Harpreet Kaur; Eric H Raabe; Eugene I Hwang; Mark A Israel
Journal:  J Pediatr Hematol Oncol       Date:  2016-05       Impact factor: 1.289

4.  Large cell/anaplastic medulloblastoma is associated with poor prognosis-a retrospective analysis at a single institute.

Authors:  Pin-I Huang; Shih-Chieh Lin; Yi-Yen Lee; Donald Ming-Tak Ho; Wan-Yuo Guo; Kai-Ping Chang; Feng-Chi Chang; Muh-Lii Liang; Hsin-Hung Chen; Yu-Ming Liu; Sang-Hue Yen; Tai-Tong Wong; Yi-Wei Chen
Journal:  Childs Nerv Syst       Date:  2017-05-09       Impact factor: 1.475

Review 5.  Sox2: regulation of expression and contribution to brain tumors.

Authors:  Sheila Mansouri; Romina Nejad; Merve Karabork; Can Ekinci; Ihsan Solaroglu; Kenneth D Aldape; Gelareh Zadeh
Journal:  CNS Oncol       Date:  2016-05-27

6.  Establishment of a novel human medulloblastoma cell line characterized by highly aggressive stem-like cells.

Authors:  Patrícia Benites Gonçalves da Silva; Carolina Oliveira Rodini; Carolini Kaid; Adriana Miti Nakahata; Márcia Cristina Leite Pereira; Hamilton Matushita; Silvia Souza da Costa; Oswaldo Keith Okamoto
Journal:  Cytotechnology       Date:  2015-09-10       Impact factor: 2.058

7.  Demographics, patterns of care, and survival in pediatric medulloblastoma.

Authors:  Emily V Dressler; Therese A Dolecek; Meng Liu; John L Villano
Journal:  J Neurooncol       Date:  2017-03-13       Impact factor: 4.130

Review 8.  Secondary oligodendroglioma after postoperative irradiation for medulloblastoma: a case report and review of the literature.

Authors:  Hong-Lin He; Ying-En Lee; Han-Jung Chen; Chao-Tien Hsu; Yu-Yi Huang; I-Wei Chang
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

9.  Endothelial Cells Promote Formation of Medulloblastoma Stem-Like Cells via Notch Pathway Activation.

Authors:  Yong Wang; Yushe Wang; Hang Chen; Qinghua Liang
Journal:  J Mol Neurosci       Date:  2017-08-30       Impact factor: 3.444

10.  EGF as a New Therapeutic Target for Medulloblastoma Metastasis.

Authors:  Jennifer Rico-Varela; Tanya Singh; Sean McCutcheon; Maribel Vazquez
Journal:  Cell Mol Bioeng       Date:  2015-06-04       Impact factor: 2.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.